News | August 05, 2025
Strides Pharma Science report Q1 FY26 PAT at Rs. 105.6 Cr
EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase
EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
The new facility will be the company’s fourth spinning plant for hollow-fiber cellulose membrane filters
He has previously served in pivotal HR leadership roles at RPG Life Sciences, Akumentis Healthcare, and Wockhardt
His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors
This achievement is part of the population-based initiative for screening, prevention, and management of Non-Communicable Diseases
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
Deepak has around 25 years of work experience with reputed companies viz. UPL Group, Teva Group, AkzoNobel India, Ranbaxy Laboratories, and Dr. Reddy’s Laboratories
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
Akums bridges the long-standing gap between paediatric syrups and conventional tablet formats
Subscribe To Our Newsletter & Stay Updated
